Communiqués NovoCure Limited

Actions

NVCR

JE00BYSS4X48

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq 22:00:00 26/08/2026			Varia. 5j.	Varia. 1 janv.
17,89 ^USD	+1,53%		-1,70%	+38,36%

24/07	NovoCure Limited : Wedbush confirme sa recommandation neutre	ZM
23/07	Transcript : NovoCure Limited, Q2 2026 Earnings Call, Jul 23, 2026

Communiqués

23/07	NovoCure: Q2 Earnings Snapshot	AQ
23/07	Novocure Reports Second Quarter 2026 Financial Results	BU
01/07	Novocure to Report Second Quarter 2026 Financial Results	BU
30/06	Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer	BU
19/06	Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)	PR
18/06	Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma	BU
30/04	NovoCure: Q1 Earnings Snapshot	AQ
30/04	Novocure Reports First Quarter 2026 Financial Results	BU
21/04	NovoCure : Financial Reports 2026 novocure corporate responsibility report	PU
01/04	Novocure to Report First Quarter 2026 Financial Results	BU
26/03	Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer	BU
02/03	Novocure to Participate in 2026 Leerink Global Healthcare Conference	AQ
02/03	Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer	BU
27/02	Novocure to Participate in 2026 Leerink Global Healthcare Conference	BU
26/02	NovoCure: Q4 Earnings Snapshot	AQ
26/02	Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update	BU
24/02	Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)	BU
11/02	U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer	BU
12/01	Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update	BU
22/12	Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference	BU
01/12	Novocure Appoints Company President Frank Leonard as Chief Executive Officer	BU
26/11	Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference	BU
12/11	Novocure to Participate in 2025 Jefferies Global Healthcare Conference	BU
30/10/25	NovoCure: Q3 Earnings Snapshot	AQ
30/10/25	Novocure Reports Third Quarter 2025 Financial Results	BU